{"id":9146,"date":"2026-10-27T15:42:49","date_gmt":"2026-10-27T10:12:49","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/cipla-share-price-today-2026-10-27\/"},"modified":"2026-10-27T15:42:51","modified_gmt":"2026-10-27T10:12:51","slug":"cipla-share-price-today-2026-10-27","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/cipla-share-price-today-2026-10-27\/","title":{"rendered":"CIPLA Share Price Today: Why CIPLA Is Falling 0.94% | 27 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: CIPLA<\/strong> \u00b7 27 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,342.30<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-0.94%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,372.70 \/ \u20b91,319.30<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,355.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>35.85 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>27 October 2026 \u00b7 02:55 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Cipla Ltd. (CIPLA) fell 0.94% on October 27, 2026, closing at \u20b91,342.30 against its previous close of \u20b91,355.00. The stock traded within a daily range of \u20b91,319.30 and \u20b91,372.70.<\/li>\n<li>Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls Moneycontrol.com<\/li>\n<li>Trading volume was 3.67 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is CIPLA share price falling on 27 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Cipla Ltd. (CIPLA) fell 0.94% on October 27, 2026, closing at \u20b91,342.30 against its previous close of \u20b91,355.00. The stock traded within a daily range of \u20b91,319.30 and \u20b91,372.70.<\/p>\n<p class=\"wt-copy\">While the broader Nifty index was essentially flat with a minor drop of 0.02%, the sector benchmark Nifty Pharma outperformed significantly, advancing 2.06% during the trading day. Cipla&#x27;s decline of 0.94% contrasted with the wider positive momentum observed across the pharmaceutical sector, reflecting individual stock headwinds or profit-taking despite favorable sectoral tailwinds.<\/p>\n<p class=\"wt-copy\">35.85 lakh shares traded by 27 October 2026 \u00b7 02:55 PM IST. This compares with a 20-day average daily volume of 9.78 lakh shares (3.67 times). The five-day average daily volume was 12.27 lakh shares. Separately, the NSE report for 26 October 2026 showed 7.70 lakh shares delivered, representing 49.74% of that day\u2019s traded volume. The same report recorded 41,675 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>profit-taking and sector divergence following Q2 earnings release<\/strong><\/p>\n<p class=\"wt-copy\">Cipla&#x27;s decline of 0.94% amid heavy volume (3.67x of 20-day average) occurred on the same day it reported its Q2FY27 financial results. While the Nifty Pharma sector gained 2.06%, the stock faced selling pressure or profit-taking as investors evaluated the reported financial metrics.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls &#8211; Moneycontrol.com<\/div>\n<div class=\"wt-card-date\">27 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls Moneycontrol.com<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Order \/ business win<\/div>\n<div class=\"wt-card-date\">3 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_03092026164718_Final_SEINT_V2f_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">4 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated September 03, 2026, titled &quot;Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda\u00ae (Pembrolizumab) in the US&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_03092026201249_Press_Release_final_signed_f.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">29.21%<\/div>\n<div class=\"wt-note\">29.21% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">20.25%<\/div>\n<div class=\"wt-note\">20.21% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">55.19%<\/div>\n<div class=\"wt-note\">54.84% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1743615_21102026092948_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Renu Jain jointly with Dinesh Jain<\/strong><span class=\"wt-note\">Immediate relative<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>15,419 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>26 September 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Anusha Jain jointly with Dinesh Jain<\/strong><span class=\"wt-note\">Immediate relative<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>15,419 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>26 September 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 20.78% on 30 September 2026. This compares with 20.56% on 30 June 2026, a change of +0.22 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 46 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND &#8211; HDFC FOCUSED FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">3.24 crore shares \u00b7 4.03%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI ELSS TAX SAVER FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.75 crore shares \u00b7 3.41%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL NIFTY50 EQUAL WEIGHT INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.33 crore shares \u00b7 2.89%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1743615_21102026092948_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Management commentary and investor conference call discussion regarding Q2FY27 margins and geographical segment performance<\/li>\n<li>Execution progress on North American pipeline products including gAdvair Diskus and the Keytruda biosimilar partnership with Qilu Pharmaceutical<\/li>\n<li>Volume trends and delivery participation following the heavy trading activity observed on October 27, 2026<\/li>\n<li>Secondary market growth trajectory for One-India and South Africa private business segments<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/cipla-share-price-today-2026-10-23\/\">CIPLA Share Price Today: Why CIPLA Is Falling 0.44% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/cipla-share-price-today-2026-09-30\/\">Why Cipla Shares Dropped 2.41% Today: Sector Trends &amp; Outlook | 30 September 2026 \u2014 30 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/cipla\/\">More CIPLA news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest CIPLA company news?<\/h3>\n<p class=\"wt-copy\">Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls Moneycontrol.com<\/p>\n<h3>How strong was CIPLA\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">35.85 lakh shares traded, 3.67 times the 20-day average daily volume. The price and volume data are dated 27 October 2026 \u00b7 02:55 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/cipla-share-price-today-2026-10-27\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/cipla-share-price-today-2026-10-27\/\"}, \"headline\": \"CIPLA Share Price Today: Why CIPLA Is Falling 0.94% | 27 October 2026\", \"description\": \"CIPLA share price fell 0.94% to \u20b91,342.30 today. See why CIPLA is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-27T15:42:38.538261+05:30\", \"dateModified\": \"2026-10-27T15:42:38.538261+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"CIPLA\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"CIPLA\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/cipla-company-news-2026-10-27.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Updates\",\"summary\":\"'Grant of stock option and employee stock appreciation rights '.\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 13:47:59\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_27102026134744_signed_Cipla_SE_20261027_Grant_Signed.pdf\",\"disclosure_text\":\"Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 27th October, 2026 (1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500087 (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C\/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Grant of stock option and employee stock appreciation rights Dear Sir \/ Madam, This is to inform you that the Company has made the following grants in terms of the Employee Stock Option Scheme 2013-A (\u201cESOS 2013-A\u201d) and the Cipla Employee Stock Appreciation Rights Scheme 2021 (\u201cESAR 2021\u201d) under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021: Sr. No. Scheme Type of Option No. of options \/ ESARs granted Vesting period \/ date Exercise period 1 ESOS 2013-A Stock options* 8,679 2 years from the grant date 5 years from the vesting date 2 ESAR 2021 Employee Stock Appreciation Rights (ESARs)** 27,140 3 years graded vesting 5 years from the vesting date * Exercise price INR 2 per stock option ** Exercise price INR 2 per equity share The Board meeting commenced today at 10:00 a.m. (IST) and concluded at 01:30 p.m. (IST). Kindly take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Neelam Padwad\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Outcome of Board Meeting held on October 27, 2026.\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 13:45:24\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_27102026134424_Signed_Cipla_SE_20261027_Appointment_of_Rashmi_Joshi_as_ID_Signed.pdf\",\"disclosure_text\":\"Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 27th October, 2026 (1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500087 (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C\/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Outcome of the Board Meeting held on 27th October, 2026 Dear Sir \/ Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015 (\u2018SEBI Listing Regulations\u2019), the Board of Directors of Cipla Limited (\u2018the Company\u2019) at its meeting held today i.e., 27 th October, 2026, approved the appointment of Ms Rashmi Joshi (DIN: 06641898), as an additional and independent director of the Company for a period of 5 years with effect from 27th October, 2026, subject to approval of the shareholders of the Company. Details required under the SEBI Listing Regulations read with SEBI circular no. HO\/49\/14\/14(7)2025-CFD- POD2\/I\/3762\/2026 dated 30th January, 2026 are provided in Annexure A. The Board meeting commenced today at 10:00 a.m. (IST) and concluded at 01:30 p.m. (IST). Kindly take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Neelam Padwad Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 Annexure A DIN 06641898 Name of Director Ms Rashmi Joshi Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise; Appointment of Ms Rashmi Joshi as an additional and independent director of the Company for a period of 5 years with effect from 27th October, 2026 to 26 th October, 2031 (both days inclusive), subject to approval of the shareholders. Date of appointment\/re-appointment\/ cessation (as applicable) & term of appointment\/re-appointment; Brief Profile (in case of appointment) Ms Rashmi Joshi is a qualified Chartered Accountant and Company Secretary with over three decades of experience across multinational organisations across FMCG, consumer durables, pharmaceuticals, and lubricants sectors. She has held leadership positions in India, the Asia-Pacific region and the Middle East, including regional and global roles, and has experience in corporate governance, risk management, financial strategy, and board governance. She has previously served as Executive Director & Chief Financial Officer of Castrol India Limited and on the boards of Godrej Industries L imited, Thirdware Solution Limited, and Castrol Philippines. She c urrently serves on the boards of GE Vernova T&D India Limited, Bharat Forge Limited, Vesuvius India Limited, Orkla India Limited, Rallis India Limited, E levate Campuses Limited, Rhea Healthcare Private Limited, and Ciel Textile Limited, Mauritius. Disclosure of relationships between directors (in case of appointment of a director). None Information as required pursuant to BSE circular with ref. no. LIST\/COMP\/14\/ 2018-19 dated 20th June 2018 and NSE circular ref. no. NSE\/CML\/2018\/24 dated 20th June 2018. Ms Rashmi Joshi is not debarred from holding the office of a director by virtue of any SEBI order or order of any other such authority.\"},{\"title\":\"Appointment\",\"summary\":\"Appointment of Ms Rashmi Joshi as Independent Director of the company w.e.f. October 27, 2026.\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 13:43:05\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_27102026134246_Signed_Cipla_SE_20261027_Appointment_of_Rashmi_Joshi_as_ID_Signed.pdf\",\"disclosure_text\":\"Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 27th October, 2026 (1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500087 (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C\/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Outcome of the Board Meeting held on 27th October, 2026 Dear Sir \/ Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015 (\u2018SEBI Listing Regulations\u2019), the Board of Directors of Cipla Limited (\u2018the Company\u2019) at its meeting held today i.e., 27 th October, 2026, approved the appointment of Ms Rashmi Joshi (DIN: 06641898), as an additional and independent director of the Company for a period of 5 years with effect from 27th October, 2026, subject to approval of the shareholders of the Company. Details required under the SEBI Listing Regulations read with SEBI circular no. HO\/49\/14\/14(7)2025-CFD- POD2\/I\/3762\/2026 dated 30th January, 2026 are provided in Annexure A. The Board meeting commenced today at 10:00 a.m. (IST) and concluded at 01:30 p.m. (IST). Kindly take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Neelam Padwad Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 Annexure A DIN 06641898 Name of Director Ms Rashmi Joshi Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise; Appointment of Ms Rashmi Joshi as an additional and independent director of the Company for a period of 5 years with effect from 27th October, 2026 to 26 th October, 2031 (both days inclusive), subject to approval of the shareholders. Date of appointment\/re-appointment\/ cessation (as applicable) & term of appointment\/re-appointment; Brief Profile (in case of appointment) Ms Rashmi Joshi is a qualified Chartered Accountant and Company Secretary with over three decades of experience across multinational organisations across FMCG, consumer durables, pharmaceuticals, and lubricants sectors. She has held leadership positions in India, the Asia-Pacific region and the Middle East, including regional and global roles, and has experience in corporate governance, risk management, financial strategy, and board governance. She has previously served as Executive Director & Chief Financial Officer of Castrol India Limited and on the boards of Godrej Industries L imited, Thirdware Solution Limited, and Castrol Philippines. She c urrently serves on the boards of GE Vernova T&D India Limited, Bharat Forge Limited, Vesuvius India Limited, Orkla India Limited, Rallis India Limited, E levate Campuses Limited, Rhea Healthcare Private Limited, and Ciel Textile Limited, Mauritius. Disclosure of relationships between directors (in case of appointment of a director). None Information as required pursuant to BSE circular with ref. no. LIST\/COMP\/14\/ 2018-19 dated 20th June 2018 and NSE circular ref. no. NSE\/CML\/2018\/24 dated 20th June 2018. Ms Rashmi Joshi is not debarred from holding the office of a director by virtue of any SEBI order or order of any other such authority.\"},{\"title\":\"Investor Presentation\",\"summary\":\"Investor Presentation\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 13:38:10\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_27102026133753_SE_Intimation_Investor_Presentation_20261027_Signed.pdf\",\"disclosure_text\":\"Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 27th October, 2026 (1) BSE Limited Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500087 (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C\/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Investor Presentation \u2013 Q2FY27 Financial Results Dear Sir \/ Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation for Q2FY27 Financial Results dated 27th October, 2026. Kindly take the above information on record. Thanking you, Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Encl: As above Prepared by: Simona Dsouza Investor Presentation Q2FY27 27-10-2026 1 DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute \\\"forward-looking statements\\\". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes \u201cg\u201d and \u201cgeneric\u201d used interchangeably indicate the generic versions of the named brand drugs. Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and\/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country. The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals. Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional. 2 Consistent Sequential Growth in Revenue and EBITDA Reflecting Sustained Business Momentum 1. Market data as per IQVIA MAT Aug\u201926 Business Performance Snapshot Revenue EBITDA PAT INR 7,404 Cr INR 1,388 Cr INR 878 Cr $ 172 MnINR 3,516 Cr 12% $ 123 Mn Highest-ever quarterly revenue Q2FY27 Q2FY27 (YoY) One India North America One Africa Emerging Markets & Europe 3 18.7% Margin 11.9% Margin Received U.S. FDA approval for gAdvair Diskus SA private growing 1.3x faster than the market1 Resilient performance amid geopolitical uncertainties $ 101 Mn 1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation Revenues INR 7,404 Cr EBITDA 1,388 Cr Q2FY27 (INR Cr) Q2FY26 (INR Cr) Total Revenue from Operations 7,404 7,589 EBITDA 1,388 1,895 EBITDA % 18.7% 25.0% PAT 878 1,351 PAT % 11.9% 17.8.% Q2FY27 (Consolidated)Revenue1 Break-up One India, 48% North America, 22% One Africa, 16% Emerging markets and Europe, 13% API and Others, 1% R&D2 INR 423 Cr | 5.7% of revenue 4 Financial Performance : Q2FY27 Branded Prescription \u2756 Cipla maintained #2 rank in overall chronic segment2 \u2756 Continued portfolio expansion with recent launch of Yurpeak, Duolin Syncrobreathe, Revesmart and Rizontem \u2756 Double-digit growth2 in chronic therapies like Respiratory, Cardiac, Urology, Anti-diabetes, and Dermatology Trade Generics \u2756 Delivered a strong double-digit QoQ growth \u2756 3 Brands with TTM revenue of > INR 100 Cr and 5 Brands with TTM revenue of INR 50 Cr to INR 100 Cr \u2756 18 new launches in Q2FY27 Consumer Health \u2756 Anchor and transitioned brands continuing to grow bigger \u2756 Haircare delivered strong double- digit growth \u2756 Omnigel, Nicotex, Prolyte and Cipladine maintained their leadership positions in the market 1. One India includes Rx, Gx and CHL | 2. Market data as per IQVIA YTD Sep\u201926 5 Highest-ever quarterly revenue of INR 3,516 Cr One India1 : Building a Sustainable Legacy for Enduring Growth 1. Market data as per IQVIA YTD Sep\u201926 | 2. Market data as per IQVIA MAT Sep\u201926 23 Brands IPM2 Brands in Top 300 ranks Key Market Highlights IPM2 Brands with revenue > INR 100 Cr 7 Therapies With IPM2 Top 5 ranks 36 Brands 1000+ Cr Foracort Biggest Respiratory Brand in IPM2 6 Largest pharma company by volume (units) in market2 Our in-house brand franchise, Dytor2, has scaled to over INR 800 Cr+ India Rx : Strengthening Our Journey with Strategic Therapeutic Focus Respiratory supremacy, with Cipla's brand franchises occupying all top 5 spots2 Steady Uptake in Key Therapies1 Growth (%) Rank 1st 2nd 7th 8th 11th 16% 20% 50% 11% 11% Dermatology Cardiac Anti-diabetic Urology Respiratory 7 Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies Respiratory Critical Care India\u2019s first once-daily nebulized bronchodilator for management of chronic obstructive pulmonary disease Galvus DM [ Vildagliptin SR+ Dapagliflozin+ Metformin SR] is indicated for the treatment of patients with type 2 diabetes mellitus. Dytor E FDC [Torsemide+Eplerenone] is indicated in the Patients with Congestive Heart Failure. Rizontem (Aztreonam and Avibactam powder for concentrate for solution for Infusion) is indicated in treatment of complicated Urinary Tract Infection including pyelonephritis, Hospital-acquired Pneumonia including ventilator- associated pneumonia and Complicated intra- abdominal infection Diabetology Cardiology Disclaimer: Product images and descriptions are included for information purposes only and do not constitute promotional or a dvertising material. Please refer to the approved prescribing information\/package insert for complete product details. Strategic Alliances during the Quarter Bispecific HER2 ADC 8 Pembrolizumab Biosimilar \u2751 Exclusive U.S. licensing and supply partnership with Qilu Pharmaceutical for QL2107, a Keytruda biosimilar. \u2751 Qilu will lead development, regulatory registration and supply, while Cipla will be responsible for U.S. commercialization. \u2751 Strengthens Cipla\u2019s oncology-focused biosimilars portfolio and supports improved access to advanced biologic therapies, subject to regulatory approval \u2751 Exclusive licensing agreement with CTTQ (SinoBiopharma Group) for TQB2102 across India, South Africa and five other emerging markets. \u2751 Advanced bispecific HER2 ADC with a differentiated 3-in-1 mechanism and potential safety\/efficacy advantages. \u2751 Strengthens Cipla\u2019s presence in ADCs and immunotherapy, targeting HER2-low breast cancer, ~50% of breast cancer cases in India. 9 9 Cold and Cough Hydration Pain Relief SmokingCessation Respi OTC One India One Africa Consumer Brands in One India Revenue : INR 427 Cr Consumer Brands in South Africa Revenue : ZAR 463 Mn Note:- Above numbers exclude sales of wellness brands through prescription channel Respi OTC Skin Infection Cold and Cough Cold and Flu Q2 FY27 : Global Consumer Wellness Franchise Pain Management\"},{\"title\":\"Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls - Moneycontrol.com\",\"summary\":\"Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls Moneycontrol.com\",\"source\":\"Moneycontrol.com\",\"published\":\"Tue, 27 Oct 2026 08:05:21 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false}],\"recent_news\":[{\"summary\":\"a press release dated October 27, 2026, titled \\\"Q2FY27 Financial Results\\\".\",\"category\":\"Press Release\",\"date\":\"27-Oct-2026 13:33:54\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_27102026133323_SE_Intimation_Press_Release_20261027_Signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Cipla Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"27-Oct-2026 13:31:22\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_27102026133100_Cipla_SE_20261027_FR_Signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.\",\"category\":\"General Updates\",\"date\":\"03-Sep-2026 16:49:25\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_03092026164718_Final_SEINT_V2f_signed.pdf\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"a press release dated September 03, 2026, titled \\\"Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda\u00ae (Pembrolizumab) in the US\\\".\",\"category\":\"Press Release\",\"date\":\"03-Sep-2026 20:13:13\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/CIPLA_03092026201249_Press_Release_final_signed_f.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"Renu Jain jointly with Dinesh Jain\",\"category\":\"Immediate relative\",\"type\":\"Buy\",\"quantity\":\"15419\",\"post_holding\":\"15556\",\"date\":\"26-Sep-2025\",\"mode\":\"Gift\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Anusha Jain jointly with Dinesh Jain\",\"category\":\"Immediate relative\",\"type\":\"Sell\",\"quantity\":\"15419\",\"post_holding\":\"Nil\",\"date\":\"26-Sep-2025\",\"mode\":\"Gift\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":29.21,\"public_pct\":70.79,\"fii_pct\":20.25,\"dii_pct\":34.94,\"mf_pct\":20.78,\"institutional_pct\":55.19,\"noninst_pct\":15.6,\"mf_scheme_count\":46,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC MUTUAL FUND - HDFC FOCUSED FUND\",\"shares\":32441264,\"pct\":4.03},{\"name\":\"SBI ELSS TAX SAVER FUND\",\"shares\":27484754,\"pct\":3.41},{\"name\":\"ICICI PRUDENTIAL NIFTY50 EQUAL WEIGHT INDEX FUND\",\"shares\":23253314,\"pct\":2.89},{\"name\":\"NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA ARB\",\"shares\":16358774,\"pct\":2.03},{\"name\":\"PARAG PARIKH ARBITRAGE FUND\",\"shares\":14982443,\"pct\":1.86}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1743615_21102026092948_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":29.21,\"previous_fii_pct\":20.21,\"previous_dii_pct\":34.63,\"previous_mf_pct\":20.56,\"previous_institutional_pct\":54.84,\"previous_mf_scheme_count\":46,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CIPLA share price fell 0.94% to \u20b91,342.30 today. See why CIPLA is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":9145,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"CIPLA Share Price Today: Why CIPLA Is Falling 0.94% | 27 October 2026","_witty_meta_description":"CIPLA share price fell 0.94% to \u20b91,342.30 today. See why CIPLA is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"CIPLA share price today","_witty_reason_label":"profit-taking and sector divergence following Q2 earnings release","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[191],"class_list":["post-9146","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-cipla"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=9146"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9146\/revisions"}],"predecessor-version":[{"id":9147,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9146\/revisions\/9147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/9145"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=9146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=9146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=9146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}